Progress in active specific immunotherapy of prostate cancer

Seminars in Surgical Oncology

Volumn 18, Issue 1, 2000, Pages 80-87

  Tjoa, Benjamin A ^a   Murphy, Gerald P ^b  

^a Northwest Biotherapeutics Inc   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Cancer vaccines; Dendritic cells; Disease progress; Hematopoietic stem cells; Histocompatibility antigens class I; Histocompatibility antigens class II; HLA A2 antigen; Immunotherapy; Interleukin 2; Messenger RNA; Monoclonal antibodies; Neoplasm staging; Peptides; Phase I clinical trials; Phase II clinical trials; Prostate specific antigen; Prostatic neoplasms; Tumor necrosis factor; Tumor infiltrating lymphocytes

Indexed keywords

ALPHA INTERFERON; ANTIANDROGEN; CANCER VACCINE; CAPROMAB PENDETIDE IN 111; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GONADORELIN AGONIST; HEMOCYANIN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; MESSENGER RNA; MONOCLONAL ANTIBODY; MUCIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

CANCER IMMUNOTHERAPY; CANCER STAGING; DENDRITIC CELL; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; VACCINES, DNA;

EID: 0033987514     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(200001/02)18:1<80::AID-SSU10>3.0.CO;2-A     Document Type: Review

References (79)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Middleton RG, Smith JA Jr, Melzer RB, Hamilton PE: Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J Urol 1986;136:422-424.
3. Hanks GE, Krall JM, Hanlon AL, et al: Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 1994;28:39-45.
4. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5 Pt 2):1831-1836.
5. Jones GW, Mettlin C, Murphy GP, et al: Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545-554.
6. Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects [Review]. J Urol 1998;160:1220-1229.
7. Iversen P: Orchidectomy and oestrogen therapy revisited [Review]. Eur Urol 1998;34 Suppl 3:7-11.
8. Scher HI, Steineck G, Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept [Review]. Urology 1995;46:142-148.
9. Krikorian JG, Portlock CS, Cooney P, Rosenberg SA: Spontaneous regression of non Hodgkin's lymphoma: a report of nine cases. Cancer 1980;46:2093-2099.
10. Ralfkiaer E, Hou-Jensen K, Mason DY, et al: Benign and malignant lymphocytic skin infiltrates: immunological patterns recognized by immunohistochemical staining with monoclonal antibodies. Adv Exp Med Biol 1985;186:1033-1041.
11. Ruiter DJ, Bhan AK, Harrist TJ, et al: Major histocompatiblity antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 1982;129:2808-2815.
12. Mitropoulos D, Kooi S, Rodriguez-Villanueva J, Platsoucas CD: Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin Exp Immunol 1994;97:321-327.
13. Kim TY, von Eschenback AC, Filaccio MD, et al: Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res 1990;50:5263-5268.
14. Zinkernagel RM, Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974;248(450):701-702.
15. Tjota A, Zhang YQ, Piedmonte MR, Lee CL: Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treatment spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor. J Urol 1991;146:177-183.
16. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233(4770):1813-1321.
17. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-1680.
18. Topalian S, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988;6: 839-853.
19. Higuchi CM, Thompson JA, Petersen FB, et al: Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991;77:2561-2568.
20. Siegall CB: Targeted toxins as anticancer agents [Review]. Cancer 1994;74(3 Suppl):1006-1012.
21. Sedlacek HH: Vaccination for treatment of tumors: a critical comment [Review]. Crit Rev Oncol 1994;5:555-587.
22. Urban JL, Schreiber H: Tumor antigens [Review]. Ann Rev Immunol 1992;10:617-644.
23. Rosenberg SA: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens [Review]. J Natl Cancer Inst 1996;88:1635-1644.
24. Engelhard VH: Structure of peptides associated with class I and class II MHC molecules [Review]. Annu Rev Immunol 1994;12: 181-207.
25. Marrack P, Kappler J: The T cell receptor [Review]. Science 1987; 238(4830):1073-1079.
26. Jenkins MK, Johnson JG: Molecules involved in T-cell costimulation [Review]. Curr Opin Immunol 1993;5:361-367.
27. Weiss A, Littman DR: Signal transduction by lymphocyte antigen-receptors [Review]. Cell 1994;76:263-274.
28. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells [Review]. Curr Opin Immunol 1992;4:619-623.
29. Horoszewicz JS, Leong SS, Kawinski E, et al: LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
30. Stone KR, Mickey DD, Wunderli H, et al: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-281.
31. Kaighn ME, Narayan KS, Ohnuki Y, et al: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
32. Claflin AJ, McKinney EC, Fletcher MA: The Dunning R3327 prostate adenocarcinoma in the Fischer-Copenhagen F1 rat: a useful model for immunological studies. Oncology 1977;34:105-109.
33. Gingrich JR. Barrios RJ, Morton RA, et al: Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
34. Sanda MG, Restifo NP, Walsh JC, et al: Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-285.
35. Bander NH, Yao D, Liu H, et al: MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997;33:233-239.
36. Sokoloff MH, Tso CL, Kaboo R, et al: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996;77:1862-1872.
37. van Moorselaar RJ, Hendriks BT, van Stratum P, et al: Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors. Cancer Res 1991;51:2329-2334.
38. Chang AY, Fisher HA, Spiers AS, Boros L: Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinoma. J Interferon Res 1985;6:713-715.
39. Bulbul MA, Huben RP, Murphy GP: Interferon-β treatment of metastatic prostate cancer. J Surg Oncol 1986;33:231-233.
40. van Haelst-Pisani CM, Richardson RL, Su J, et al: A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer 1992;70:2310-2312.
41. Maffezzini M, Simonato A, Fortis C: Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 1996;28:282-286.
42. Vieweg J, Rosenthal FM, Bannerji R, et al: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994;54:1760-1765.
43. Moody DB, Robinson JC, Ewing CM, et al: Interleukin-2 transfected prostate cancer cells generate a local antitumor in vivo. Prostate 1994;24:244-251.
44. Simons JW, Mikhak B: Ex-vivo gene therapy using cytokin-transduced tumor vaccines: molecular and clinical pharmacology [Review]. Semin Oncol 1998;25:661-676.
45. Morales A, Nickel JC, Downey J, et al: Immunotherapy of an experimental adenocarcinoma of the prostate. J Urol 1995;153:1706-1710.
46. Hrouda D, Baban B, Dunsmuir WD, et al: Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL 172). Br J Urol 1998;82:568-573.
47. Foti AG, Cooper JF, Herschman H, Malvaez RR: Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 1977;297:1357-1361.
48. Israeli RS, Powell CT, Corr JG, et al: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
49. Wang MC, Papsidero LD, Kuriyama M, et al: Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981;2:89-96.
50. Tjoa B, Boynton A, Kenny G, et al: Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996;28:65-69.
51. Xue BH, Zhang Y, Sosman JA, Peace DJ: Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997;30:73-78.
52. Correale P, Walmsley K, Nieroda C, et al: In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997;89:293-300.
53. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic-acid phosphatase peptide. Prostate 1998;36:129-138.
54. Kim JJ, Trivedi NN, Wilson DM, et al: Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine [published erratum appears in Oncogene 199;18:2411]. Oncogene 1998;17:3125-3135.
55. Slovin SF, Kelly WK, Scher HI: Immunological approaches for the treatment of prostate cancer [Review]. Semin Urol Oncol 1998;16:53-59.
56. Gonzalez G, Crombet T, Catala M, et al: A novel cancer vaccine composed of human-recombinant epidermal-growth factor linked to carrier protein: report of a pilot clinical trial. Ann Oncol 1998;9:431-435.
57. Knight SC, Stagg AJ: Antigen-presenting cell types [Review]. Curr Opin Immunol 1993;5:374-382.
58. Mellman I, Turley SJ, Steinman RM: Antigen processing for amateurs and professionals [Review]. Trends Cell Biol 1998;8:231-237.
59. Steinman RM: The dendritic cell system and its role in immunogenicity [Review]. Annu Rev Immunol 1991;9:271-296.
60. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995;55:1099-1104.
61. rd, et al: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-69.
62. Wu L, Li CL, Shortman K: Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med 1996;184:903-911.
63. Tsujitani S, Kakeii Y, Watanabe A, et al: Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990;66:2012-2016.
64. Knight SC, Hunt R, Dore C, Medawar PB: Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985;82:4495-4497.
65. Grabbe S, Bruvers S, Gallo RL, et al: Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-3661.
66. Flamand V, Sornasse T, Thielemans K, et al: Murine dendritic cells pulsed in vitro with tumor antigen induce tumour resistance in vivo. Eur J Immunol 1994;24:605-610.
67. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-1302.
68. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
69. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
70. Mukherji B, Chakraborty NG, Yamasaki S, et al: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
71. 111Indium-labeled monoclonal antibody CYT-356. J Urol 1994;152(6 Pt 1):1952-1955.
72. Kawakami M, Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;15:2321-2324.
73. Murphy G, Tjoa B, Ragde H, et al: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
74. Tjoa BA, Simmons SJ, Bowes VA, el al: Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
75. Murphy GP, Tjoa BA, Simmons SJ, et al: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38:73-78.
76. Murphy GP, Tjoa BA, Simmons SJ, et al: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999;39:54-59.
77. Tjoa BA, Erickson SJ, Bowes VA, et al: Follow-up evaluation of prostate cancer patients with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272-278.
78. Simmons SJ, Tjoa BA, Rogers M, et al: GM-CSF as systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999; 39:291-297.
79. Tjoa BA, Simmons SJ, Elgamal A, et al: Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999;40:125-129.